19,900 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Acquired by Synovus Financial Corp

Synovus Financial Corp acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 19,900 shares of the biopharmaceutical company’s stock, valued at approximately $465,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Teachers Retirement System of The State of Kentucky acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at about $1,039,000. Neo Ivy Capital Management acquired a new position in TG Therapeutics in the third quarter valued at approximately $2,358,000. Barclays PLC boosted its position in TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock worth $8,117,000 after purchasing an additional 158,323 shares in the last quarter. Castleark Management LLC acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $3,948,000. Finally, Wellington Management Group LLP increased its holdings in shares of TG Therapeutics by 12.7% during the 3rd quarter. Wellington Management Group LLP now owns 73,320 shares of the biopharmaceutical company’s stock valued at $1,715,000 after purchasing an additional 8,249 shares in the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Trading Down 7.4 %

Shares of TGTX stock opened at $31.07 on Thursday. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84. The company’s 50-day moving average price is $29.24 and its 200-day moving average price is $23.74. The stock has a market cap of $4.84 billion, a price-to-earnings ratio of -310.67 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.73 earnings per share. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on TGTX shares. JPMorgan Chase & Co. increased their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. The Goldman Sachs Group increased their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. StockNews.com upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 14th. HC Wainwright increased their price target on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, TG Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $40.67.

Insider Activity at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now directly owns 100,195 shares in the company, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.50% of the stock is currently owned by insiders.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.